Responsiveness of the EuroQol EQ-5D and Hospital Anxiety and Depression Scale (HADS) in rheumatoid arthritis patients receiving tocilizumab

Traki, L.; Rostom, S.; Tahiri, Latifa; Bahiri, R.; Harzy, Taoufik; Abouqal, Rédouane; Hajjaj–Hassouni, N.

doi:10.1007/s10067-014-2609-z

Cited by 48 publications

(35 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Tocilizumab yields its anti-inflammatory effects via an IL-6 receptor blockade, which involves inhibiting the IL-6 ligand from binding to IL-6R and sIL-6R [145,146]. Preliminary evidence has suggested that tocilizumab may have variable effects on improving mood symptoms in patients with RA [147,148]. In addition, there are other anti-IL-6R compounds that are currently pending clinical approval.…”

Section: Adjunctive Anti-inflammatory Treatment For Mddmentioning

confidence: 98%

Novel investigational drugs targeting IL-6 signaling for the treatment of depression

Fonseka

McIntyre

Soczynska

et al. 2015

Expert Opinion on Investigational Drugs

View full text Add to dashboard Cite

To improve drug development for the treatment of MDD, there is a critical need to identify promising targets. Target identification will require guidance from a strategic framework such as The Research Domain Criteria, and convincing evidence relating known targets to brain function under both physiological and pathological conditions. Although current evidence provides rationale for administering anti-IL-6 treatments in MDD, further studies confirming safety, target affinity and therapeutic benefits are warranted.

show abstract

Section: Adjunctive Anti-inflammatory Treatment For Mddmentioning

confidence: 98%

Novel investigational drugs targeting IL-6 signaling for the treatment of depression

Fonseka

McIntyre

Soczynska

et al. 2015

Expert Opinion on Investigational Drugs

View full text Add to dashboard Cite

show abstract

“…The use of tocilizumab, a humanized antibody against IL-6 receptor, or sirukumab, a humanized antibody against IL-6 have been proposed as novel antidepressant therapeutics (Traki et al, 2014;Hsu et al, 2015). Two ongoing clinical trials will examine the antidepressant effects of tocilizumab and sirukumab among patients with treatment-refractory major depression (www.clinicaltrials.gov).…”

Section: Anti-inflammatory Therapeuticsmentioning

confidence: 99%

Immune and Neuroendocrine Mechanisms of Stress Vulnerability and Resilience

Ménard

Pfau

Hodes

et al. 2016

Neuropsychopharmacol

293

201

View full text Add to dashboard Cite

Diagnostic criteria for mood disorders including major depressive disorder (MDD) largely ignore biological factors in favor of behavioral symptoms. Compounding this paucity of psychiatric biomarkers is a need for therapeutics to adequately treat the 30-50% of MDD patients who are unresponsive to traditional antidepressant medications. Interestingly, MDD is highly prevalent in patients suffering from chronic inflammatory conditions, and MDD patients exhibit higher levels of circulating pro-inflammatory cytokines. Together, these clinical findings suggest a role for the immune system in vulnerability to stress-related psychiatric illness. A growing body of literature also implicates the immune system in stress resilience and coping. In this review, we discuss the mechanisms by which peripheral and central immune cells act on the brain to affect stress-related neurobiological and neuroendocrine responses. We specifically focus on the roles of pro-inflammatory cytokine signaling, peripheral monocyte infiltration, microglial activation, and hypothalamic-pituitary-adrenal axis hyperactivity in stress vulnerability. We also highlight recent evidence suggesting that adaptive immune responses and treatment with immune modulators (exogenous glucocorticoids, humanized antibodies against cytokines) may decrease depressive symptoms and thus represent an attractive alternative to the current antidepressant treatments.

show abstract

“…Background: Many patients with rheumatoid arthritis (RA) experience anxiety and depression, with higher presence of these disorders in those with poorer outcome [1]. Previous experiences found relationships with psychological status and disease activity in patients with active disease [2,3]. Further evidences are needed to asses the impact on residual RA activity during treatment.…”

Section: Discussionmentioning

confidence: 99%

AB0399 Rheumatoid Arthritis Impact of Disease: A Global Disease Assessment Index that Correlates with Activity and Function in RA Patients

et al. 2015

View full text Add to dashboard Cite

BackgroundPain is a major feature in rheumatoid arthritis (RA), often occurring with other symptoms and functional impairment, which are difficult to assess. An increasing interest has been dedicated to the patient perspective in the assessment of RA, by using indexes that approach other health domains such as fatigue, well-being and sleep disturbance. Rheumatoid Arthritis Impact of Disease (RAID) includes seven domains (pain, function, fatigue, sleep disturbance, physical and psychological wellbeing, sleep disturbance and coping), which enable the assessment of the global impact of the disease, through the patient perspective.ObjectivesTo compare, in a cohort of patients with rheumatoid arthritis, the impact of the disease assessed with RAID questionnaire and Health Assessment Questionnaire (HAQ), and to identify possible association with disease activity (as assessed by DAS28-3v).MethodsCross-sectional study, enrolling outpatients attending a Rheumatology Department, diagnosed with RA. All patients answered both HAQ and RAID at the same visit; DAS28-3v was determined. Statistical analysis with SPSS, version 18; a p value <0.05 with a 95% confidence interval was assumed.ResultsAmong the 68 patients enrolled, 45 were male; age was 61.15±13.6 years. Mean RAID value was 3.59±2.24; in 21 patients, RAID was ≥5. As expected, the question with higher mean value was that referring to pain (3.93±2.64). Mean HAQ value was 0.3±0.47 and mean DAS28-3v was 2.74±1.06 (corresponding to low disease activity).In our cohort, the increase in RAID value is significantly correlated with an increase in HAQ value – particularly when RAID≥4 (p=0.01). All items assessed by RAID are significantly associated with HAQ value – being the highest correlation identified for functional impairment (p=0.009). RAID value was also associated with DAS28-3v (p=0.02). No correlation was found between RAID and age and no significant difference between genders was identified.ConclusionsThis work demonstrates the usefulness of RAID in the assessment of RA, presenting a good correlation with HAQ, that assesses functional impairment - being this correlation stronger for higher RAID values. In our cohort, there was also a correlation between RAID and disease activity, as assessed using DAS28-3v. The evaluation of RA patients should include autofill indexes that assess global impact of the disease; RAID gathers the features to be included among those indexes.ReferencesDougados M, Brault Y, Logeart I, van der Heijde D, Gossec L, Kvien T. Defining cut-off values for disease activity states and improvement scores for patient-reported outcomes: the exemple of the Rheumatoid Arthritis Impact of Disease (RAID). Arthritis Res Ther. 2012 May 30;14(3).Disclosure of InterestNone declared

show abstract

Responsiveness of the EuroQol EQ-5D and Hospital Anxiety and Depression Scale (HADS) in rheumatoid arthritis patients receiving tocilizumab

Cited by 48 publications

References 29 publications

Novel investigational drugs targeting IL-6 signaling for the treatment of depression

Novel investigational drugs targeting IL-6 signaling for the treatment of depression

Immune and Neuroendocrine Mechanisms of Stress Vulnerability and Resilience

AB0399 Rheumatoid Arthritis Impact of Disease: A Global Disease Assessment Index that Correlates with Activity and Function in RA Patients

Contact Info

Product

Resources

About